Clinical Trial

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Study acronym: FINER
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2020-12-01; most recent amendment 2026-03-23.
Status change: Recruiting → Active, Not Recruiting 2024-05-08
Status change: Not Yet Recruiting → Recruiting 2021-01-13
Trial Details
NCT Number NCT04650581
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Hoffmann-La Roche
Conditions Breast Cancer
Enrollment 250 participants
Start Date 2021-01-27
Primary Completion 2025-05-23 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13